Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 193,646 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Gift · Disposed 80,000 · Balance 193,646 F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 39,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · derivative · entry 7 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,371 Underlying: Class A Common Stock · 31,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,219 | $5.47 | $88,717.93 |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,998 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-008951 · wk-form4_1709674816.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-007998 · wk-form4_1709241999.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 31,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,556 | $5.71 | $94,534.76 |
DisclosureSEC source: 0001628280-24-007998 · wk-form4_1709241999.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,846 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-007998 · wk-form4_1709241999.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 29,302 | $4.13 | $120,920.56 |
DisclosureSEC source: 0001209191-23-045846 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,739 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.94 to $4.22, inclusive. The reporting person undertakes to provide to Amneal Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 23,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041087 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. F4 · derivative.expiration_date: On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,571 | $3.10 | $35,870.10 |
DisclosureSEC source: 0001209191-23-041087 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,041 F3 · shares: Represents shares of Class A Common Stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 23,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041087 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of Class A Common Stock, par value $0.01 per share (the "Class A Common Stock") issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 397,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016929 · doc4.xml · derivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,554 Underlying: Class A Common Stock · 397,554 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · shares: Represents a performance-based restricted stock unit grant of 198,777 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 198,777 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 198,777 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 198,777 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F7 · balance_after: Represents a performance-based restricted stock unit grant of 198,777 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 198,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016929 · doc4.xml · derivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,777 Underlying: Class A Common Stock · 198,777 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 39,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016929 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,754 Underlying: Class A Common Stock · 39,251 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 19,685 | $1.92 | $37,795.20 |
DisclosureSEC source: 0001209191-23-016929 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,517 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 39,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016929 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · derivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,742 Underlying: Class A Common Stock · 31,371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 12,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · derivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,121 | $2.09 | $33,692.89 |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,951 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · nonDerivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 6,846 | $2.09 | $14,308.14 |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,701 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 12,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-015521 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014118 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,663 Underlying: Class A Common Stock · 31,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 17,557 | $2.16 | $37,923.12 |
DisclosureSEC source: 0001209191-23-014118 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,201 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:30 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014118 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 23,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-040624 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,095 Underlying: Class A Common Stock · 23,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. F4 · derivative.expiration_date: On August 1, 2020, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,582 | $3.18 | $36,830.76 |
DisclosureSEC source: 0001209191-22-040624 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,096 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 23,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-040624 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 16,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028154 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 8,353 | $3.40 | $28,400.20 |
DisclosureSEC source: 0001209191-22-028154 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,584 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 16,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028154 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 314,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · derivative · entry 8 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,010 Underlying: Class A Common Stock · 314,010 shares Expires not disclosed F7 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · shares: Represents a performance-based restricted stock unit grant of 157,005 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 157,005 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 157,005 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 157,005 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · balance_after: Represents a performance-based restricted stock unit grant of 157,005 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 157,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · derivative · entry 7 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,005 Underlying: Class A Common Stock · 157,005 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · derivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,113 Underlying: Class A Common Stock · 31,370 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 12,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · derivative · entry 5 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,346 Underlying: Class A Common Stock · 12,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 15,733 | $4.45 | $70,011.85 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,281 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · nonDerivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 6,192 | $4.45 | $27,554.40 |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,644 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:17 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 12,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016047 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:08 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 31,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014133 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,325 Underlying: Class A Common Stock · 31,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:08 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 16,434 | $4.59 | $75,432.06 |
DisclosureSEC source: 0001209191-22-014133 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,490 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:08 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 31,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014133 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 20:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 23,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044367 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,189 Underlying: Class A Common Stock · 23,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On August 1, 2021, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. F4 · derivative.expiration_date: On August 1, 2021, the reporting person was granted 69,284 restricted stock units vesting in three equal installments beginning on June 30, 2021. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 20:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 11,583 | $5.12 | $59,304.96 |
DisclosureSEC source: 0001209191-21-044367 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,262 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 20:03 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 23,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-044367 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:54 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 16,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031565 · doc4.xml · derivative · entry 3 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,656 Underlying: Class A Common Stock · 16,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:54 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 8,353 | $5.20 | $43,435.60 |
DisclosureSEC source: 0001209191-21-031565 · doc4.xml · nonDerivative · entry 2 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,750 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2021 Filed May 11, 2021 18:54 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 16,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-031565 · doc4.xml · nonDerivative · entry 1 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 12,346 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016034 · doc4.xml · derivative · entry 6 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,692 Underlying: Class A Common Stock · 12,346 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:36 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 6,192 | $5.18 | $32,074.56 |
DisclosureSEC source: 0001209191-21-016034 · doc4.xml · nonDerivative · entry 4 BOYER ANDREW S · CIK 0001239546 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,448 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.